Curt Mazur

Dr. Curt Mazur


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
GRGregory J. Raymond
Gregory J. Raymond
HZHien Tran Zhao
Hien Tran Zhao
BRBrent Race
Brent Race
LRLynne D. Raymond
Lynne D. Raymond
KWKatie Williams
Katie Williams
SVSonia M Vallabh
Sonia M Vallabh
Prion disease is a fatal, incurable neurodegenerative disease of humans and other mammals caused by conversion of cellular prion protein (PrP C ) into a self-propagating neurotoxic conformer (prions; PrP Sc ). Strong genetic proofs of concept support lowering PrP expression as a therapeutic strategy. Antisense oligonucleotides (ASOs) can provide a practical route to lowering 1 target mRNA in the brain, but their development for prion disease has been hindered by 3 unresolved issues from prior work: uncertainty about mechanism of action, unclear potential for efficacy against established prion infection, and poor tolerability of drug delivery by osmotic pumps. Here, we test ASOs delivered by bolus intracerebroventricular injection to intracerebrally prion-infected WT mice. Prophylactic treatments given every 2–3 months extended survival times 61%–98%, and a single injection at 120 days after infection, near the onset of clinical signs, extended survival 55% (87 days). In contrast, a nontargeting control ASO was ineffective. Thus, PrP lowering is the mechanism of action of ASOs effective against prion disease in vivo, and infrequent — or even single — bolus injections of ASOs can slow prion neuropathogenesis and markedly extend survival, even when initiated near clinical signs. These findings should empower development of PrP-lowering therapy for prion disease.

17 November 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
THTracy L Hagemann
Tracy L Hagemann
BPBerit Powers
Berit Powers
NLNi-Hsuan Lin
Ni-Hsuan Lin
AMAhmed F. Mohamed
Ahmed F. Mohamed
KDKaterina L. Dague
Katerina L. Dague
AMAlbee Messing
Albee Messing
Gfap -antisense prevents disease with early treatment and reverses clinical phenotypes with late treatment in a rat model of Alexander disease.

8 August 2020 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
JSJenna M. Sullivan
Jenna M. Sullivan
CMCurt Mazur
Curt Mazur
DWDaniel A. Wolf
Daniel A. Wolf
LHLaura Horky
Laura Horky
NCNicolas Currier
Nicolas Currier
AVAjay Verma
Ajay Verma
Background: The intrathecal (IT) dosing route introduces drugs directly into the CSF to bypass the blood–brain barrier and gain direct access to the CNS. We evaluated the use of convective forces acting on the cerebrospinal fluid as a means for increasing rostral delivery of IT dosed radioactive tracer molecules and antisense oligonucleotides (ASO) in the monkey CNS. We also measured the cerebral spinal fluid (CSF) volume in a group of cynomolgus monkeys. Methods: There are three studies presented, in each of which cynomolgus monkeys were injected into the IT space with radioactive tracer molecules and/or ASO by lumbar puncture in either a low or high volume. The first study used the radioactive tracer 64Cu-DOTA and PET imaging to evaluate the effect of the convective forces. The second study combined the injection of the radioactive tracer 99mTc-DTPA and ASO, then used SPECT imaging and ex vivo tissue analysis of the effects of convective forces to bridge between the tracer and the ASO distributions. The third experiment evaluated the effects of different injection volumes on the distribution of an ASO. In the course of performing these studies we also measured the CSF volume in the subject monkeys by Magnetic Resonance Imaging. Results: It was consistently found that larger bolus dose volumes produced greater rostral distribution along the neuraxis. Thoracic percussive treatment also increased rostral distribution of low volume injections. There was little added benefit on distribution by combining the thoracic percussive treatment with the high-volume injection. The CSF volume of the monkeys was found to be 11.9 ± 1.6 cm3. Conclusions: These results indicate that increasing convective forces after IT injection increases distribution of molecules up the neuraxis. In particular, the use of high IT injection volumes will be useful to increase rostral CNS distribution of therapeutic ASOs for CNS diseases in the clinic.

1 March 2017 in Journal of Neuroscience Methods
Verified
Journal Article
Closed access
CMCurt Mazur
Curt Mazur
BFBethany Fitzsimmons
Bethany Fitzsimmons
FKFredrik Kamme
Fredrik Kamme
BNBrandon Nichols
Brandon Nichols
BPBerit Powers
Berit Powers
EWEd Wancewicz
Ed Wancewicz

22 March 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
MMMeredith A. Mortberg
Meredith A. Mortberg
HZHien T. Zhao
Hien T. Zhao
ARAndrew Reidenbach
Andrew Reidenbach
JGJuliana E. Gentile
Juliana E. Gentile
EKEric Kuhn
Eric Kuhn
EMEric Vallabh Minikel
Eric Vallabh Minikel
Prion protein (PrP) concentration controls the kinetics of prion replication and is a genetically and pharmacologically validated therapeutic target for prion disease. In order to evaluate PrP concentration as a pharmacodynamic biomarker and assess its contribution to known prion disease risk factors, we developed and validated a plate-based immunoassay reactive for PrP across 6 species of interest and applicable to brain and cerebrospinal fluid (CSF). PrP concentration varied dramatically across different brain regions in mice, cynomolgus macaques, and humans. PrP expression did not appear to contribute to the known risk factors of age, sex, or common PRNP genetic variants. CSF PrP was lowered in the presence of rare pathogenic PRNP variants, with heterozygous carriers of P102L displaying 55%, and D178N just 31%, of the CSF PrP concentration of mutation-negative controls. In rodents, pharmacologic reduction of brain Prnp RNA was reflected in brain parenchyma PrP and, in turn in CSF PrP, validating CSF as a sampling compartment for the effect of PrP-lowering therapy. Our findings support the use of CSF PrP as a pharmacodynamic biomarker for PrP-lowering drugs and suggest that relative reduction from individual baseline CSF PrP concentration may be an appropriate marker for target engagement.

28 February 2019 in BMC Genomics
Verified
Journal Article
Open access
PDF file
CCChristine E. Cho
Christine E. Cho
SDSagar S. Damle
Sagar S. Damle
EWEdward V. Wancewicz
Edward V. Wancewicz
SMSwagatam Mukhopadhyay
Swagatam Mukhopadhyay
CHChristopher E. Hart
Christopher E. Hart
FKFredrik Kamme
Fredrik Kamme
Microglia are multifunctional cells that are key players in brain development and homeostasis. Recent years have seen tremendous growth in our understanding of the role microglia play in neurodegeneration, CNS injury, and developmental disorders. Given that microglia show diverse functional phenotypes, there is a need for more precise tools to characterize microglial states. Here, we experimentally define gene modules as the foundation for describing microglial functional states. In an effort to develop a comprehensive classification scheme, we profiled transcriptomes of mouse microglia in a stimulus panel with 96 different conditions. Using the transcriptomic data, we generated fine-resolution gene modules that are robustly preserved across datasets. These modules served as the basis for a combinatorial code that we then used to characterize microglial activation under various inflammatory stimulus conditions. The microglial gene modules described here were robustly preserved, and could be applied to in vivo as well as in vitro conditions to dissociate the signaling pathways that distinguish acutely inflamed microglia from aged microglia. The microglial gene modules presented here are a novel resource for classifying and characterizing microglial states in health and disease.